Abstract:Lecithin:cholesterol acyltransferase (LCAT) exhibits α-activity on high-density and β-activity on low-density lipoproteins. However, the molecular determinants governing LCAT activation by different apolipoproteins remain elusive. Uncovering these determinants would offer the opportunity to design and explore advanced therapies against dyslipidemias. Here, we have conducted coarse-grained and all-atom molecular dynamics simulations of LCAT with nanodiscs made with α-helical amphiphilic peptides either derived from apolipoproteins A1 and E (apoA1 and apoE) or apoA1 mimetic peptide 22A that was optimized to activate LCAT. This study aims to explore what drives the binding of peptides to our previously identified interaction site in LCAT. We hypothesized that this approach could be used to screen for binding sites of LCAT in different apolipoproteins and would provide insights to differently localized LCAT activities. Our screening approach was able to discriminate apoA1 helixes 4, 6, and 7 as key contributors to the interaction with LCAT supporting the previous research data. The simulations provided detailed molecular determinants driving the interaction with LCAT: the formation of hydrogen bonds or salt bridges between peptides E4 or D4 and LCAT S236 or K238 residues. Additionally, salt bridging between R7 and D73 was observed, depending on the availability of R7. Expanding our investigation to diverse plasma proteins, we detected novel LCAT binding helixes in apoL1, apoB100, and serum amyloid A. Our findings suggest that the same binding determinants, involving E4 or D4 -S236 and R7-D73 interactions, influence LCAT β-activity on low-density lipoproteins, where apoE and or apoB100 are hypothesized to interact with LCAT. Atherosclerotic cardiovascular disease is caused by the accumulation of cholesterol in arteries. A developing class of therapies against it attempt to promote the efficiency of high-density lipoprotein (HDL), which removes cholesterol from peripheral cells. Importantly, this includes cholesterol-laden macrophages, also known as foam cells, present in atherosclerotic lesions. In this context, one strategy focuses on improving the cholesterol carrying capacity of HDL by improving the enzymatic activity of lecithin:cholesterol acyltransferase (LCAT). Although LCAT remodels HDL to accept more cholesterol, it also remodels low-density lipoprotein (LDL), which has an opposite effect to HDL. In other words, LDL brings cholesterol to peripheral cells. We hypothesize that this may be part of the reason why LCAT activation hasn't shown clinical success thus far. In order to investigate this, we must selectively inhibit LCAT's activity on LDL, which in turn requires us to know which amino acids take part in the LCAT-HDL and LCAT-LDL interactions. In this article, we've used molecular dynamics simulations to reveal these amino acids. This information will be useful in the optimization of LCAT and HDL based therapies against atherosclerosis as well as in the design of HDL-like drug delivery systems whose properties are affected by LCAT.

The promise of enzymes in therapy of hyperlipidemia

Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency in the 21(st) century

Fabrication of Enzyme-Immobilized Halloysite Nanotubes for Affinity Enrichment of Lipase Inhibitors from Complex Mixtures.

Improved catalytic properties of immobilized lipases by the presence of very low concentrations of detergents in the reaction medium

Enzyme preparations for the correction of digestion

Stabilization of Immobilized Lipases by Intense Intramolecular Cross-Linking of Their Surfaces by Using Aldehyde-Dextran Polymers

Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipase-deficient mice and agonist-like function of pancreatic lipase in pancreatic cells.

Systematic evaluation of lecithin:Cholesterol acyltransferase binding sites in apolipoproteins via peptide based nanodiscs: Regulatory role of charged residues at positions 4 and 7

The Initial Human Atherosclerotic Lesion and Lipoprotein Modification-A Deep Connection

Pancreatic and mucosal enzymes in choline phospholipid digestion

The effects of dietary phospholipids enriched with phosphatidylethanolamine on bile and red cell membrane lipids in humans

Contemporary hypolipemic therapy: possibilities of novel hypolipemic drugs in correction of lipid metabolism disorders. Review

Enhancement of high-density lipoprotein-associated protease inhibitor activity prevents atherosclerosis progression

Angiopoietin-like Proteins and Lipoprotein Lipase: The Waltz Partners That Govern Triglyceride-Rich Lipoprotein Metabolism? Impact on Atherogenesis, Dietary Interventions, and Emerging Therapies

Soybean-Derived Peptides Attenuate Hyperlipidemia by Regulating Trans-Intestinal Cholesterol Excretion and Bile Acid Synthesis

Topo-dynamic characteristics of human plasma VLDL apolipoproteins and efficiency of triacylglycerol hydrolysis by lipoprotein lipase

The intrinsic instability of the hydrolase domain of lipoprotein lipase facilitates its inactivation by ANGPTL4-catalyzed unfolding

Stabilization of Lipase in Polymerized High Internal Phase Emulsions

New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect?

Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins

Role of Hepatic Lipase and Endothelial Lipase in High-Density Lipoprotein—Mediated Reverse Cholesterol Transport